Accelerated blood clearance and hypersensitivity by PEGylated liposomes containing TLR agonists

Area of Science:

• Immunology
• Nanotechnology
• Pharmacology

Background:

• Toll-like receptor (TLR) agonists show promise for cancer therapy by stimulating the innate immune system.
• Clinical use is limited by severe adverse effects from systemic immune activation.
• Liposomal drug delivery systems offer potential to mitigate these issues by modifying drug biodistribution and circulation.

Purpose of the Study:

• To investigate barriers to administering TLR agonists in polyethylene glycosylated (PEGylated) liposomes.
• To evaluate the impact of formulation, administration route, and schedule on therapeutic outcomes.
• To assess the role of anti-PEG antibodies in adverse reactions and drug clearance.

Main Methods:

• Formulation of TLR agonists in PEGylated liposomes.
• Intravenous administration in preclinical models.
• Monitoring of biodistribution, blood clearance, and immune responses (antibody titers).
• Analysis of hypersensitivity reactions and their correlation with antibody isotypes.

Main Results:

• PEGylated liposomes formulated with TLR agonists induced high titers of anti-PEG antibodies.
• Multiple intravenous administrations led to accelerated blood clearance of the liposomes.
• Acute hypersensitivity reactions were observed, linked to anti-PEG IgG antibody opsonization.
• Anti-PEG IgM antibodies did not appear to cause similar reactions.

Conclusions:

• Anti-nanoparticle immune responses, specifically anti-PEG antibodies, pose a significant challenge for systemic immunotherapy.
• Careful design and evaluation of nanoparticle delivery systems are crucial to overcome immunogenicity.
• These findings emphasize the need to address anti-PEG antibody formation for successful clinical translation of liposomal TLR agonists.